Neutrexin

NeuTrexin®

Trimetrexate glucuronate, see there.

Neutrexin

A brand name for TRIMETREXATE.
References in periodicals archive ?
the main products are synagis, cytogam, respigam, ethyol, neutrexin and hexalen.
The company believes that sales of NeuTrexin and Hexalen were negatively affected during the second quarter by transitional factors relating to the assumption of full responsibility for promotion of these products in the United States by U.
Bioscience had expanded its sales force to provide national coverage for Neutrexin and Hexalen.
Addressing another major clinical and regulatory objective, Clarke remarked that NeuTrexin is currently indicated for the treatment of pneumocystis carinii pneumonia, an opportunistic infection associated with AIDS, and stated that the company is conducting two Phase III clinical trials of NeuTrexin in combination with 5-FU and leucovorin, the current standard of care for treatment of patients with colorectal cancer.
The reductions in Hexalen and NeuTrexin sales were affected, the company believes, by the commitment of sales and marketing resources to the launch and ongoing promotion of Ethyol in the United States.
Reduction in Hexalen sales was also affected by new competitive pressures and NeuTrexin sales were affected by a reduction in the incidence and severity of Pneumocystis carinii pneumonia (PCP) in patients infected with the human immunodeficiency virus (HIV).
Sales of the company's other drug products, Hexalen(R) and NeuTrexin(R), were reduced from the prior year period due to the commitment of sales and marketing resources to the launch of Ethyol in the United States, to new product competitive pressures affecting sales of Hexalen, and to a reduction in the incidence and severity of Pneumocystis carinii pneumonia (PCP) in patients infected with the human immunodeficiency virus (HIV), affecting sales of NeuTrexin.
Research and development costs increased due to higher personnel and clinical trial expenses reflecting the company's Phase III clinical programs for Ethyol in radiation protection and NeuTrexin in colorectal cancer.
The expanded relationship with ALZA for co-promotion of Hexalen and NeuTrexin represents an important opportunity to broaden the coverage for these products in the medical community, while facilitating the coordination of selling activities for Ethyol between U.
Increased licensing income was principally due to a one-time fee received from an affiliate of Eli Lilly and Company for product distribution rights in Canada for Hexalen, NeuTrexin and Ethyol(R) (amifostine), the company's cytoprotective agent.
In Phase II studies, NeuTrexin has demonstrated efficacy in the treatment of specific cancers and is under active clinical development as an anticancer agent both in the United States and in Europe.
In Canada, Hexalen (altretamine) was approved in August 1994 for use as a first-line and salvage treatment for ovarian cancer, while NeuTrexin (trimetrexate glucuronate) was approved in December 1993 for the treatment of Pneumocystis carinii pneumonia (PCP), the most common life-threatening infection associated with AIDS.